DEA Explicitly Designates HHC as a Schedule I Controlled Substance

The Drug Enforcement Administration has issued a final rule creating a specific listing and drug code for hexahydrocannabinol, widely known as HHC, within Schedule I of the Controlled Substances Act. The agency maintains that HHC was already controlled under broader tetrahydrocannabinol definitions, but this administrative action establishes a dedicated entry to streamline regulatory tracking and enforcement. As a result, commercial entities marketing semi-synthetic HHC products under the guise of the Farm Bill face direct federal prohibition.

Clinical & Patient Impact

Patients who have relied on over-the-counter HHC products for pain, sleep, or anxiety relief will lose access as storefronts and online vendors clear inventory to avoid federal liability. Clinicians should prepare for inquiries from individuals who may unknowingly continue using illicit supplies or pivot to other untested novel cannabinoids. This development underscores the clinical necessity of directing patients toward regulated, laboratory-tested natural cannabis options rather than manufactured gray-market analogues.